Literature DB >> 24251135

Resistant prolactinoma: Is it monoclonal or polyclonal?

K V S Hari Kumar1, Pitambar Prusty.   

Abstract

Prolactinomas are solitary benign neoplasms and resistance to dopamine agonists occur in a small percentage of prolactinomas. Multiple pituitary adenomas are reported in less than 1% of pituitary adenomas and rarely result in resistant prolactinoma. We recently encountered an interesting patient of hyperprolactinemia with multiple pituitary microadenomas. Dopamine agonist use resulted in prolactin normalization and subsequent pregnancy resulted in drug withdrawal. Repeat evaluation after delivery showed a macroprolactinoma and dopamine agonist therapy resulted in biochemical cure without reduction in tumor size. We report the case for its presentation with multiple microadenomas progressing to macroprolactinoma suggesting polyclonal in origin.

Entities:  

Keywords:  Multiple pituitary adenoma; polyclonal; resistant prolactinoma

Year:  2013        PMID: 24251135      PMCID: PMC3830281          DOI: 10.4103/2230-8210.119534

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


  7 in total

1.  Double adenomas of the pituitary: transcription factors Pit-1, T-pit, and SF-1 identify cytogenesis and differentiation.

Authors:  R A Jastania; K O Alsaad; M Al-Shraim; K Kovacs; S L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 2.  Advances in the treatment of prolactinomas.

Authors:  Mary P Gillam; Mark E Molitch; Gaetano Lombardi; Annamaria Colao
Journal:  Endocr Rev       Date:  2006-05-26       Impact factor: 19.871

3.  Double pituitary adenomas: six surgical cases.

Authors:  T Sano; H Horiguchi; B Xu; C Li; A Hino; M Sakaki; S Kannuki; S Yamada
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

4.  A double pituitary adenoma presenting as a prolactin-secreting tumor with partial response to medical therapy. Case report.

Authors:  Claire I Coiré; Harley S Smyth; Dominic Rosso; Eva Horvath; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

5.  Molecular screening of pituitary adenomas for gene mutations and rearrangements.

Authors:  V Herman; N Z Drazin; R Gonsky; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1993-07       Impact factor: 5.958

Review 6.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

7.  Multiple adenomas of the human pituitary. A retrospective autopsy study with clinical implications.

Authors:  G Kontogeorgos; K Kovacs; E Horvath; B W Scheithauer
Journal:  J Neurosurg       Date:  1991-02       Impact factor: 5.115

  7 in total
  3 in total

1.  Isolated double adrenocorticotropic hormone-secreting pituitary adenomas: A case report and review of the literature.

Authors:  Jiujun Pu; Zhiming Wang; Hui Zhou; Ailing Zhong; Kai Jin; Lunliang Ruan; Gang Yang
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

Review 2.  Double pituitary adenomas are most commonly associated with GH- and ACTH-secreting tumors: systematic review of the literature.

Authors:  Elizabeth Ogando-Rivas; Andrew F Alalade; Jerome Boatey; Theodore H Schwartz
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

3.  Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.

Authors:  Hua Gao; Fei Wang; Xiaolei Lan; Chuzhong Li; Jie Feng; Jiwei Bai; Lei Cao; Songbai Gui; Lichuan Hong; Yazhuo Zhang
Journal:  BMC Cancer       Date:  2015-04-12       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.